Xyosted

BP increases can occur and can increase the risk for major adverse cardiovascular (CV) events (eg, MI, stroke, death). Consider baseline cardiovascular risk and ensure BP is controlled prior to initiation. Monitor BP approx. 6 weeks after initiating and periodically thereafter for new onset hypertension or exacerbations; re-evaluate benefits/risks if CV risk factors or disease develops. Measure total testosterone trough levels after 6 weeks of dosing, then 6 weeks after dose adjustment, and periodically during treatment. Monitor hematocrit prior to initiation and every 3 months during therapy; if elevation occurs, withhold until acceptable level; permanently discontinue if elevated after restarting treatment. Increased risk of worsening of BPH; monitor. Evaluate for prostate cancer prior to and during therapy. Monitor for venous thromboembolism; discontinue if suspected. Testosterone and/or other anabolic androgenic steroid abuse. Discontinue and evaluate if signs/symptoms of hepatic dysfunction (eg, jaundice) occur. Pre-existing cardiac, renal, or hepatic disease (discontinue if edema occurs). Possible sleep apnea in patients with obesity or chronic lung diseases. Monitor lipid profile (esp. after starting therapy), serum calcium (in cancer patients at risk of hypercalcemia/hypercalciuria) periodically. Risk of depression or suicide. May suppress spermatogenesis. Elderly. Not for use in women.